Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

RRoyalty Pharma plc

EconomyAI buildoutMarket MapFundsWatchlist
Log in
R

Royalty Pharma plc

$58.52Close · Sep 22, 2026
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • History
  • Insider Transactions
Loading financials
Income statement income statement flow. Revenue $674.14M. Net result $81.49M.

Income statement revenue $674.14M (+16.5% YoY).Operating income $133.12M (-36.5% YoY).Pre-tax result $81.49M (-12.0% YoY).Net result $81.49M (-12.0% YoY).

  • Financial Royalty Assets: $638.03M (+15.9% YoY)
  • Royalty Income Other: $36.11M (+27.9% YoY)
  • Provision for changes in expected cash flows from financial royalty assets: $268.22M
  • Provision for credit losses on unfunded commitments: $13.07M (-85.9% YoY)
  • Research and development funding expense: $97.85M (-67.4% YoY)
  • General and administrative expenses (includes $107,356 and $91,044 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively, and $229,648 and $91,747 for the six months ended June 30, 2026 and 2025, respectively; see Note 4): $161.89M (-9.9% YoY)
  • Other expense: $51.63M (-55.9% YoY)